Pharmacologic treatments for covid-19 patients

Aspirin vs Standard care/Placebo

This comparison will not be updated. Last search date 28 Feb, 2022.

On March 17, 2022tudy Ghati, 2021 was excluded from the analysis since the paper is not anymore accessible on SSRN nor on published elsewhere. We have contacted authors for further details.

Outpatients

Forest plots
(last update: 2022-04-29)

Hospitalized patients

Forest plots
(last update: 2022-03-17)

Summary of findings
(last update: 2022-06-01)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=371

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04498273
ACTIV-4B
Connors JM, JAMA, 2021
Full text
Commentary
Public/non profit

Aspirin

Apixaban prophylactic

Apixaban therapeutic

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated in 52 centers in USA N=657
Some concerns
Details

Full description

NCT04381936; ISRCTN50189673
RECOVERY-ASA
Horby P, Lancet, 2021
Full text
Full text
Commentary
Commentary
Mixed

Aspirin

Standard care

RCT Patients with suspected and confirmed COVID-19 (mild-critical) admitted to 167 hospitals in the UK, 2 hospitals in Indonesia and 2 hospitals in Nepal N=14892
Some concerns
Details

Full description